Spirometry

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

Retrieved on: 
Wednesday, March 27, 2024
Principal, Annual, Fungal infection, TFF, COVID, Intubation, International Society, Part, Patient, Biomarker, IPA, Spirometry, EAP, Mortality, Lung transplantation, Microsoft Access, Potential, Safety, Kidney, Heart, Pharmaceutical industry

FORT WORTH, Texas , March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced updated data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

Key Points: 
  • “Based on the totality of these clinical data, we believe TFF TAC and TFF VORI have the potential to establish a new and significantly improved form of delivery for these two life-saving medicines.
  • The updated safety and efficacy data are based on the cutoff date of March 8, 2024.
  • The ongoing Phase 2 trial of TFF TAC is an open-label study in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity.
  • The Company will host a conference call today at 4:30 pm Eastern Time, to discuss updated data for the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) clinical programs.

New Campaign Highlights How Certain Jobs Can Increase a Person's Risk for Lung Disease

Retrieved on: 
Tuesday, April 9, 2024
Pneumonia, Emphysema, Bronchitis, Disease, Tobacco, Agriculture, Risk, Urinary tract infection, Spirometry, Fatigue, Smoke, Quality of life, Sputum, Dust, Mucus, Smoking, Wheeze, American Lung Association, COPD, Air pollution, Workplace, Phlegm, Ageing, Mining, Nursing

CHICAGO, April 9, 2024 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) impacts 11.7 million people living in the U.S. While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD. To help people identify workplace risk factors and encourage them to speak with their healthcare provider if they are experiencing symptoms, the American Lung Association is launching a campaign to raise awareness for occupational COPD. 

Key Points: 
  • While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD.
  • COPD, which includes chronic bronchitis and emphysema, is a long-term lung disease that makes it hard to breathe.
  • Many workplaces may expose workers to risk factors for COPD, but the leading job types that increase risk for chronic lung disease include agriculture, mining and manufacturing.
  • Early treatment of a chronic lung disease, including reducing the exposure, can help lead to better health outcomes.

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

Retrieved on: 
Friday, March 22, 2024
PET/CT, Contract research organization, Biotechnology, Sarcoidosis, Disease, Patient safety, Patient, Tablet, Spirometry, Messenger, Quality of life, Biology, Royal, Fibrosis, Clinical trial, European, Arrest, Safety, Pharmacokinetics, MOC, Phase, KITE, FDA, FVC, ECG, Granuloma, Pharmaceutical industry

The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.

Key Points: 
  • The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.
  • As part of the trial, patients will take a daily fixed dose of 25 mg OATD-01 or placebo tablets for 12 weeks.
  • Patient safety will be monitored regularly through laboratory tests, neurological examinations and ECG and spirometry.
  • The study will involve approximately 20-30 centres in the US, the European Union, Norway and the UK.

Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE

Retrieved on: 
Friday, March 15, 2024
Hypercapnia, Respironics, VAPO, Business, Patient, Mechanical ventilation, Spirometry, Business development, Quality of life, Respiratory disease, OTCQX, NIV, COPD, FDA, HME, Hospital

EXETER, N.H., March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.

Key Points: 
  • EXETER, N.H., March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX: VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference.
  • Dr. Jessica Whittle, Chief Medical Officer of Vapotherm, emphasized the company's commitment to improving the lives of hypercapnic patients in the home.
  • "(1)
    The highly anticipated Access365 home ventilator will be unveiled at MEDTRADE Dallas on March 27th.
  • Joe Army, President and CEO of Vapotherm, underscored the significance of the solution, stating, "Vapotherm is committed to supporting patients both in and out of the hospital.

Breathe Change: Lung Health Foundation Launches First of Three Landmark Policy Forums on Thursday, March 7

Retrieved on: 
Monday, March 4, 2024
Chairperson, Clinical Practice, RSV, Education, Building, Spirometry, Hospital, Overalls, Asthma, Pneumonia, Assembly, Hope, LHF, Long-term care, Climate change, Patient, Policy, Health policy, Lung cancer, Health professional, Diagnosis, Wildfire, Mortality, Public, Research, Radon, Health insurance

LHF is the nation's leading non-profit organization dedicated to supporting and empowering individuals living with lung conditions across Canada.

Key Points: 
  • LHF is the nation's leading non-profit organization dedicated to supporting and empowering individuals living with lung conditions across Canada.
  • The session showcases the best-of-the-best in COPD and lung disease research, diagnosis and treatment modalities, and policy initiatives.
  • Dawn Bowdish, Executive Director, Firestone Institute for Respiratory Health and Dr. Maya de Zoysa, Respirologist, West Nipissing General Hospital.
  • For those navigating the labyrinth of lung disease, LHF offers an expansive array of disease-specific support programs and resources.

Mitsubishi Tanabe Pharma America to Showcase Presentations on ALS Research at 2024 MDA Clinical & Scientific Conference

Retrieved on: 
Friday, March 1, 2024
Real-World Evidence, Massachusetts General Hospital, Spirometry, Data mart, ALS, Doctor of Philosophy, Interim analysis, Edaravone, M.S, Hospital, Conference, Natural history, State university system, Abstract, CDM, SVC, MDA, Phase 4, Episcopal conference, MTPA, Pharmaceutical industry

JERSEY CITY, N.J., March 1, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla., March 3-6.

Key Points: 
  • JERSEY CITY, N.J., March 1, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of five abstracts in amyotrophic lateral sclerosis (ALS) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held in Orlando, Fla., March 3-6.
  • "These presentations reinforce our commitment to making a positive impact on the ALS community by better understanding disease markers and outcomes and providing important information on our treatment options for clinical practice."
  • Interim Analysis of the Radicava/Edaravone Findings in Biomarkers from ALS (REFINE-ALS) Study (James Berry, M.D., M.P.H.
  • Real-World Evidence on Treatment Retention, Safety, and Tolerability of Edaravone in Canadian Patients With Amyotrophic Lateral Sclerosis (Dung Pham, PhD; MTPA-CA)

Ozone and PM2.5 Exposure is Associated with Nasal Key Driver Gene Expression in People with Asthma

Retrieved on: 
Thursday, February 15, 2024
Air pollution, AAAAI, Pollutant, Ozone, Research, Multimedia, FGL2, CLC, Female, Asthma, FEV1, Master of Philosophy, RNA, TNFRSF10C, Gene expression, Rhinitis, White, Patient, Journal, MPH, Gene, Dermatitis, Spirometry, American Academy, Pharmaceutical industry

MILWAUKEE, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Nasal key driver gene expression representing T-cell mediated immune processes is associated with ozone and fine particulate matter (PM2.5) exposure in people with asthma according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting.

Key Points: 
  • MILWAUKEE, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Nasal key driver gene expression representing T-cell mediated immune processes is associated with ozone and fine particulate matter (PM2.5) exposure in people with asthma according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting.
  • In the study, researchers identified six key driver genes for ozone and three key driver genes for PM2.5 exposure.
  • FGL2, previously reported as a master regulator of asthma, was the most upstream key driver for both ozone and PM2.5.
  • The findings suggest exposure to ozone and PM2.5 in individuals with asthma is associated with nasal key driver gene expression representing T-cell mediated immune processes.

NuvoAir’s Air Next Spirometer Is FDA-Approved for In-Home Use

Retrieved on: 
Tuesday, January 30, 2024
Medical Devices, FDA, Hospitals, Health Technology, Telemedicine, Virtual Medicine, Cardiology, Biotechnology, Health, General Health, Spirometry, Travel, Heart, MD, Atmosphere of Earth, Asthma, Patient, Next, Clinical trial, Air Next, COPD, ATS, ALS, Medical device

Today, NuvoAir Medical announced its innovative Air Next Spirometer has received formal 510(k) clearance for in-home use as a full spirometer.

Key Points: 
  • Today, NuvoAir Medical announced its innovative Air Next Spirometer has received formal 510(k) clearance for in-home use as a full spirometer.
  • 510(k) approval empowers NuvoAir to scale and expand clinical operations to ensure no patient with heart or lung conditions is left behind.
  • 510(k) clearance allows Air Next to conduct full spirometry at home, providing extremely valuable clinical data that ensures patients can be monitored continuously.
  • “Air Next brings the reliability of in-clinic spirometry right to our patients’ hands,” says Furat Shawki, General Manager of Clinical Trials at NuvoAir.

AllerVie Health Expands Technology Infrastructure to Prioritize Innovation and Patient Experience

Retrieved on: 
Tuesday, January 23, 2024
Software, Practice Management, General Health, Health, Medical Devices, Health Technology, Technology, Apps, Applications, Cystic fibrosis, Patient, Chronic obstructive pulmonary disease, EMR, Asthma, Allergy, Communication, COPD, DLCO, Spirometry, Growth

"We are excited about our technology transformations this year and how they are enabling us to advance patient care and outcomes," said Chris Roussos, CEO of AllerVie Health.

Key Points: 
  • "We are excited about our technology transformations this year and how they are enabling us to advance patient care and outcomes," said Chris Roussos, CEO of AllerVie Health.
  • Key highlights of digital advancements include:
    In 2023, AllerVie Health expanded its deployment of a state-of-the-art pulmonary function testing solution to 30 clinics nationwide.
  • AllerVie Health implemented a new electronic medical record (EMR) system in 14 clinics across Florida and Georgia during 2023.
  • AllerVie Health's collaboration with a prominent digital health company specializing in respiratory health management broadens the utilization of a portable digital respiratory health tool and app across a more extensive range of clinics within the AllerVie Health network.

Mitsubishi Tanabe Pharma America Announces Presentations in ALS at 34th International Symposium on ALS/MND

Retrieved on: 
Tuesday, December 5, 2023
Data mart, SVC, Research, Safety, ALS, MGH, State university system, Motor Neurone Disease Association, Spirometry, Disease, CET, MTPA, Part, MNDA, Medical Affairs Bureau, Abstract, CDM, Edaravone, Massachusetts General Hospital, NCRI, Hospital, Pharmaceutical industry, Communications satellite, Telehealth, Biomarker, Patient, Optum

JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.

Key Points: 
  • JERSEY CITY, N.J., Dec. 5, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that four abstracts in amyotrophic lateral sclerosis (ALS) will be presented at the Motor Neurone Disease Association (MNDA) 34th International Symposium on ALS/MND, being held in Basel, Switzerland, from December 6-8.
  • MTPA's posters will be displayed during poster sessions held in the Event Halle on December 6 and 7.
  • A Preliminary Analysis of Oral Edaravone-Treated Patients with Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database (Malgorzata Ciepielewska, M.S.
  • ; State University of New York Upstate Medical University)
    Poster Session B (Part 1), 5:45 p.m. – 6:45 p.m. CET, Dec. 7